The dysregulation of biometal (Cu, Zn, Fe) homeostasis and oxidative stress in brain cells 2 have been found to impact on accumulation of amyloid β (Aβ), a major putative factor 3 involved in early Alzheimer's disease (AD) pathogenesis [1] . The regulation of metal ion 4 homeostasis in the cytoplasm is strongly influenced by copper chaperone for superoxide 5 dismutase (CCS) and Cu,Zn-superoxide dismutase (SOD-1) [2] . The dynamic interplay of 6
properly folded CCS and SOD-1 guarantees that free Cu and Zn ions are being complexed by 7 these metal proteins and do not catalyze oxidation processes of proteins, lipids, DNA, and 8 other molecules in the cells [2] . When these physiological complexation mechanisms do not 9 function properly, oxidative stress and dys-homeostasis of Cu and Zn metabolism may give 10 rise to misfolding, accumulation and aggregation of amyloid β peptides [2]. The outcome of 11 these pathological processes may lead to incurable chronically progressive neurodegenerative 12 diseases such as Alzheimer's disease [1, 2] . Several therapeutic strategies and nearly all 13 medications used or suggested as Aβ inhibitors, including metal-chelating agents or radical 14 scavengers, at present time, aim at the treatment of AD symptoms only and may either be 15 toxic, lack specificity or have unknown mechanisms of action in vivo [2, 3] . 16
17
The aim of this article is to give a short review on the interaction of metal ions with novel and 18 early herbal compounds derived from Ginkgo biloba, and their possible role in the treatment 19 of early Alzheimer's disease. Though Ginkgo biloba leaf extracts are generally administered 20 to treat dementia syndroms in older AD patients (> 65 years old), no data is available on 21 possible effects of recombinant plant-made copper chaperones from Ginkgo biloba in younger 22 AD patients (> 50 years old) with preclinical stages of disease. 23
24

INTERACTION OF HERBAL DRUGS WITH METAL IONS 25
The medical community, including the pharmaceutical industry, as well as AD patients, have 26 become aware of the well-known antioxidant effects of ancient herbal medications, namely 27
Ginkgo biloba leaf extracts [4] . A complex mixture of flavonoids and terpenoids are thought 28 to represent the main bioactive compounds of these plant extracts [5] . For example, the 29 flavonol quercetin, a major compound of Ginkgo extract, was found to interact with Cu 2+ and 30 Fe 3+ [6] . However, an ideal therapeutic drug to dissolve Aβ peptides would involve a 31 compound selective for Cu + , Zn 2+ and Fe 3+ [7] . A meta-analysis by Birks and Evans revealed 32 that commercially available medicinal plant extracts (EGb 761 ® Ginkgo biloba leaf extract) 33 have no consistent pattern of any clinical benefit associated with Ginkgo biloba for people 34 with dementia or cognitive impairment [4] . Furthermore, the results from the study of He and 1 colleagues suggested that high doses of herbal remedies can even be toxic to cells [8] . Thus, 2
Ginkgo biloba extracts may induce unwanted side-effects and may also lack specificity as to 3 the binding of Cu + and Zn 2+ in the cytoplasm. Likely, these extracts neither reduce metal-4 based oxidative stress efficiently nor contribute to the homeostatic control of biometals in 5 human cells, though in vitro studies have shown that gingkolides may protect against the 6 synapse damage and cognitive loss seen during the early stages of AD [5] . However [10]. Drugs derived from recombinant proteins potentially have greater efficacy and fewer 20 side-effects than small organic molecules (e.g., Cu orotate, quercetin), because their action 21 can be more precisely targeted towards the Aβ plaque formation as a major putative factor in 22 the pathogenesis of Alzheimer's disease rather than the treatment of AD symptoms [11] . The 23 dysfunction of the CCS-SOD-1 interplay may be one specific but major mechanism in the 24 pathogenesis of Alzheimer's disease. It is a well-known fact that biometals (Fe, Zn, Cu) are 25 accumulated in the brain with normal ageing [13] . Important factors affecting the balance 26 between metal ion accumulation and deficiency are, for example, environmental exposure, 27 ageing or drug interaction [14] . The inability of the human organism to maintain the metal ion 28 homeostasis due to improperly folded CCS and SOD molecules in brain cells is suggested as 29 causal for preclinical stages, development and progression of AD and other neurodegenerative 30 diseases [9, 11, 15] . 31
32
For the restoration and modulation of metal ion homeostasis in the treatment of AD, we have 33 proposed a novel class of pharmacologically active plant ingredients as antioxidants: copper chaperone for superoxide dismutase derived from medicinal plants (e.g., Ginkgo biloba) 1 [9, 11] . In molecular farming approaches transgenic plants (e.g., tobacco) may serve as an 2 efficient production platform for medications in regard to protein yield, quality and stability 3 [16] . Recombinant CCS proteins produced in transgenic plants may cross the blood-brain 4 barrier and are relatively free from side-effects [9, 11] . Being properly-folded, plant-made 5 CCS may have the ability to bind and deliver Cu + /Cu 2+ , Zn 2+ and Fe 3+ ions and to normalize 6 the SOD-1 activity via specific protein-protein interactions in the central nervous system and 7 peripherally [9,11]. 8 9
In contrast to plant-made pharmaceuticals (PMPs), organisms like yeast, mammals or bacteria 10 used for molecular farming approaches, express properly folded as well as improperly folded 11 recombinant therapeutic proteins. These medications may lack stability and pharmacological 12 efficiency in protein-misfolding diseases, e.g., Alzheimer's disease [16] . Furthermore, PMPs 13 may have several advantages in terms of cost scalability or safety issues compared to the other 14 genetically modified organisms [16] . Possibly suitable for use in younger AD patients (> 50 years), CCS proteins derived from 19 medicinal plants may be targeted more towards prevention of Aβ plaque formation as a major 20 putative factor involved in AD pathogenesis, rather than the treatment of AD symptoms in 21 older patients (> 65 years). We suggest that recombinant plant-made CCS derived from 22
Ginkgo biloba leaves might be promising in the treatment of patients suffering from 23 preclinical symptoms of Alzheimer's disease. 24 25 
